Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Eupraxia Pharmaceuticals logo
$5.38 -0.09 (-1.66%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX)

Key Stats

Today's Range
$5.19
$5.19
50-Day Range
$5.05
$5.64
52-Week Range
$2.20
$6.20
Volume
1,111 shs
Average Volume
13,363 shs
Market Capitalization
$193.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

EPRX MarketRank™: 

Eupraxia Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 499th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Eupraxia Pharmaceuticals has a consensus price target of $11.00, representing about 101.1% upside from its current price of $5.47.

  • Amount of Analyst Coverage

    Eupraxia Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Eupraxia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eupraxia Pharmaceuticals is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eupraxia Pharmaceuticals is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Eupraxia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.66% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eupraxia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.66% of the float of Eupraxia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Eupraxia Pharmaceuticals has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eupraxia Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Eupraxia Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
Receive EPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EPRX Stock News Headlines

Trump’s Plan May Undo 1933’s Biggest Financial Injustice
Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real wealth for early adopters In 1933, Executive Order 6102 forced everyday Americans to hand over their gold at a fixed rate. Everyday citizens lost a sizable amount of their hard earned wealth at the stroke of FDR's pen.tc pixel
See More Headlines

EPRX Stock Analysis - Frequently Asked Questions

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX stock has increased by 72.6% and is now trading at $5.47.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05.

Top institutional investors of Eupraxia Pharmaceuticals include Scotia Capital Inc. (3.59%), Bank of Montreal Can (0.10%), Ingalls & Snyder LLC (0.10%) and JPMorgan Chase & Co. (0.05%).

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

Last Earnings
8/12/2025
Today
9/12/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EPRX
Previous Symbol
NASDAQ:EPRX
CIK
1581178
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$9.00
Potential Upside/Downside
+101.1%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.50 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-626.84%
Return on Assets
-118.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.72
Quick Ratio
8.72

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
35,960,000
Free Float
N/A
Market Cap
$196.70 million
Optionable
N/A
Beta
1.49

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:EPRX) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners